Overactive wake signalling as a possible cause of chronic insomnia
This 2 minute video from Professor Dr. med. G. Hajak, professor of Psychiatry and Neurology, provides a concise introduction to the role of overactive wake signalling as a possible cause for chronic insomnia.
Watch Prof. Dr. med. G. Hajak’s insightful summary in the video now.
Promotional material from Idorsia Pharmaceuticals UK Ltd.
QUVIVIQ™▼ (daridorexant) is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.1
References
1 – QUVIVIQ™ (daridorexant) Idorsia Pharmaceuticals Ltd, Summary of Product Characteristics.
2 – Roch C, et al. Psychopharmacology. 2021; 238(10): 2693–2708.
3 – NICE Clinical Knowledge Summary (CKS) Insomnia: Scenario: Managing long-term insomnia (more than 3 months duration). Available at: https://cks.nice.org.uk/topics/insomnia/management/managing-insomnia/. Updated May 2025. Accessed June 2025.
4 – Mignot E, et al. Lancet Neurol. 2022; 21(2): 125–139.
This information is intended for UK healthcare professionals.
Adverse events must be reported. Healthcare professionals are asked to report any suspected adverse reactions via http://www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google play or Apple App store. Adverse events should also be reported to ds.safety.uk@idorsia.com.
